Michael Pacini

847 total citations
8 papers, 572 citations indexed

About

Michael Pacini is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Michael Pacini has authored 8 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Michael Pacini's work include Epigenetics and DNA Methylation (3 papers), Hemoglobinopathies and Related Disorders (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Michael Pacini is often cited by papers focused on Epigenetics and DNA Methylation (3 papers), Hemoglobinopathies and Related Disorders (3 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Michael Pacini collaborates with scholars based in United States, Italy and Germany. Michael Pacini's co-authors include M. De Lena, Cristina Oliva, Cesare Gridelli, G Luporini, Mauro Antimi, Giovanni Luca Frassineti, Vito Lorusso, C. F. Pollera, Héctor Soto Parrà and Gianni Bonadonna and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Michael Pacini

7 papers receiving 557 citations

Peers

Michael Pacini

SURGE

ONCOL

PFM

PRM

MB

Tony Dhillon United Kingdom

Masakatsu Yonezumi Japan

T Takizawa Japan

Mario L. Marques‐Piubelli United States

Yunxia Huang China

Jochen Casper Germany

Joël Gsponer Switzerland

James Strauss United States

Ekaterini Boleti United Kingdom

Lixin Yang China

Tony Dhillon United Kingdom

Michael Pacini

72 ×0.3

SURGE

326 ×1.5

ONCOL

172 ×1.0

PFM

61 ×0.5

PRM

120 ×1.0

MB

Citations per year, relative to Michael Pacini Michael Pacini (= 1×) peers Tony Dhillon

Countries citing papers authored by Michael Pacini

Since Specialization

Citations

This map shows the geographic impact of Michael Pacini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Pacini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Pacini more than expected).

Fields of papers citing papers by Michael Pacini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Pacini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Pacini. The network helps show where Michael Pacini may publish in the future.

Co-authorship network of co-authors of Michael Pacini

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Pacini. A scholar is included among the top collaborators of Michael Pacini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Pacini. Michael Pacini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Molokie, Robert E., Santosh L. Saraf, Michael Pacini, et al.. (2023). Translating an HPFH-Mechanism into Oral Small Molecule Therapy for Beta-Hemoglobinopathies: Clinical Proof-of-Principle. Blood. 142(Supplement 1). 2524–2524.

2.

Lulla, Rishi, Stewart Goldman, Tohru Yamada, et al.. (2016). Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. Neuro-Oncology. 18(9). 1319–1325. 117 indexed citations

3.

Molokie, Robert E., Donald Lavelle, Michel Gowhari, et al.. (2016). Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. Blood. 128(22). 124–124. 2 indexed citations

4.

Lavelle, Donald, Michel Gowhari, Michael Pacini, et al.. (2014). Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease. Blood. 124(21). 90–90. 2 indexed citations

5.

Rosen, Fred, et al.. (2004). Severe Dermatologic Reactions at Multiple Sites After Paclitaxel Administration. Annals of Pharmacotherapy. 38(2). 238–241. 6 indexed citations

6.

Filippo, Carlotta De, Cristina Luceri, Giovanna Caderni, et al.. (2002). Mutations of the APC Gene in Human Sporadic Colorectal Cancers. Scandinavian Journal of Gastroenterology. 37(9). 1048–1053. 27 indexed citations

7.

Santoro, Armando, Henning Bredenfeld, Liliana Devizzi, et al.. (2000). Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study. Journal of Clinical Oncology. 18(13). 2615–2619. 176 indexed citations

8.

Lorusso, Vito, C. F. Pollera, Mauro Antimi, et al.. (1998). A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. European Journal of Cancer. 34(8). 1208–1212. 242 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact